D
Esperion Therapeutics, Inc.
ESPR
$1.50
$0.000.00%
D
Sell
10/23/2024Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 10/23/2024 due to an increase in the volatility index and total return index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 10/23/2024 due to an increase in the volatility index and total return index.
E
Sell
10/8/2024Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 10/8/2024 due to a decline in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 10/8/2024 due to a decline in the volatility index.
D
Sell
9/19/2024Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 9/19/2024 due to an increase in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 9/19/2024 due to an increase in the volatility index.
E
Sell
9/3/2024Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 9/3/2024 due to a decline in the volatility index and total return index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 9/3/2024 due to a decline in the volatility index and total return index.
D
Sell
8/15/2024Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 8/15/2024 due to an increase in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 8/15/2024 due to an increase in the volatility index.
E
Sell
8/5/2024Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 8/5/2024 due to a decline in the volatility index and growth index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 8/5/2024 due to a decline in the volatility index and growth index.
D
Sell
7/17/2024Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 7/17/2024 due to an increase in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 7/17/2024 due to an increase in the volatility index.
E
Sell
6/28/2024Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 6/28/2024 due to a decline in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 6/28/2024 due to a decline in the volatility index.
D
Sell
6/7/2024Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 6/7/2024 due to an increase in the total return index and volatility index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 6/7/2024 due to an increase in the total return index and volatility index.
E
Sell
5/23/2024Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 5/23/2024 due to a decline in the volatility index, solvency index and valuation index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 5/23/2024 due to a decline in the volatility index, solvency index and valuation index.
D
Sell
5/7/2024Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 5/7/2024 due to an increase in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 5/7/2024 due to an increase in the volatility index.
E
Sell
4/17/2024Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 4/17/2024 due to a significant decline in the growth index, volatility index and solvency index. Operating cash flow declined 91.75% from -$19.33M to -$37.06M, EBIT declined 53.88% from -$27.53M to -$42.37M, and earnings per share declined from -$0.3687 to -$0.5013.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 4/17/2024 due to a significant decline in the growth index, volatility index and solvency index. Operating cash flow declined 91.75% from -$19.33M to -$37.06M, EBIT declined 53.88% from -$27.53M to -$42.37M, and earnings per share declined from -$0.3687 to -$0.5013.
D
Sell
2/12/2024Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 2/12/2024 due to an increase in the volatility index and total return index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 2/12/2024 due to an increase in the volatility index and total return index.
E
Sell
1/26/2024Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 1/26/2024 due to a decline in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 1/26/2024 due to a decline in the volatility index.
D
Sell
1/10/2024Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 1/10/2024 due to a significant increase in the growth index, volatility index and valuation index. Total revenue increased 31.73% from $25.79M to $33.97M, EBIT increased 25.7% from -$37.06M to -$27.53M, and operating cash flow increased 21.92% from -$24.75M to -$19.33M.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 1/10/2024 due to a significant increase in the growth index, volatility index and valuation index. Total revenue increased 31.73% from $25.79M to $33.97M, EBIT increased 25.7% from -$37.06M to -$27.53M, and operating cash flow increased 21.92% from -$24.75M to -$19.33M.
E
Sell
3/14/2023Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D on 3/14/2023 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 2.68 to 2.17, debt to equity increased from -1.85 to -1.56, and EBIT declined 2.14% from -$41.62M to -$42.51M.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D on 3/14/2023 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 2.68 to 2.17, debt to equity increased from -1.85 to -1.56, and EBIT declined 2.14% from -$41.62M to -$42.51M.
D
Sell
2/9/2023Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index and volatility index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index and volatility index.
E
Sell
2/8/2023Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
5/16/2022Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from E+ on 05/16/2022.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D on 05/13/2022.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D on 05/13/2022.
D
Sell
5/6/2022Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from E+ on 5/6/2022 due to a significant increase in the growth index and solvency index. Earnings per share increased from -$1.7674 to -$0.9307, operating cash flow increased 32.43% from -$57.71M to -$38.99M, and EBIT increased 22.72% from -$55.63M to -$42.99M.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from E+ on 5/6/2022 due to a significant increase in the growth index and solvency index. Earnings per share increased from -$1.7674 to -$0.9307, operating cash flow increased 32.43% from -$57.71M to -$38.99M, and EBIT increased 22.72% from -$55.63M to -$42.99M.
E
Sell
11/3/2021Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 11/3/2021 due to a decline in the volatility index, growth index and solvency index. Earnings per share declined from -$1.67 to -$2.62, EBIT declined 71.35% from -$32.53M to -$55.75M, and total revenue declined 64.56% from $40.66M to $14.41M.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 11/3/2021 due to a decline in the volatility index, growth index and solvency index. Earnings per share declined from -$1.67 to -$2.62, EBIT declined 71.35% from -$32.53M to -$55.75M, and total revenue declined 64.56% from $40.66M to $14.41M.
D
Sell
10/11/2021Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 10/11/2021 due to an increase in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 10/11/2021 due to an increase in the volatility index.
E
Sell
9/22/2021Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 9/22/2021 due to a decline in the volatility index and total return index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 9/22/2021 due to a decline in the volatility index and total return index.
D
Sell
9/3/2021Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 9/3/2021 due to an increase in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 9/3/2021 due to an increase in the volatility index.
E
Sell
8/18/2021Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 8/18/2021 due to a decline in the total return index and volatility index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 8/18/2021 due to a decline in the total return index and volatility index.
D
Sell
8/4/2021Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to D- from D on 8/4/2021 due to a large decline in the growth index, volatility index and total return index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to D- from D on 8/4/2021 due to a large decline in the growth index, volatility index and total return index.
D
Sell
2/24/2021Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from D- on 2/24/2021 due to a large increase in the growth index, valuation index and total return index. Total revenue increased 151.45% from $3.83M to $9.64M, and operating cash flow increased 20.91% from -$86.67M to -$68.55M.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from D- on 2/24/2021 due to a large increase in the growth index, valuation index and total return index. Total revenue increased 151.45% from $3.83M to $9.64M, and operating cash flow increased 20.91% from -$86.67M to -$68.55M.
D
Sell
2/8/2021Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 2/8/2021 due to an increase in the volatility index and total return index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 2/8/2021 due to an increase in the volatility index and total return index.
E
Sell
1/20/2021Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 1/20/2021 due to a decline in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 1/20/2021 due to a decline in the volatility index.
D
Sell
1/4/2021Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 1/4/2021 due to an increase in the volatility index and valuation index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 1/4/2021 due to an increase in the volatility index and valuation index.
E
Sell
12/18/2020Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 12/18/2020 due to a decline in the volatility index, total return index and valuation index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 12/18/2020 due to a decline in the volatility index, total return index and valuation index.
D
Sell
12/1/2020Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 12/1/2020 due to an increase in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 12/1/2020 due to an increase in the volatility index.
E
Sell
11/12/2020Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 11/12/2020 due to a decline in the volatility index and total return index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to E+ from D- on 11/12/2020 due to a decline in the volatility index and total return index.
D
Sell
11/9/2020Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to D- from D on 11/9/2020 due to a substantial decline in the growth index, total return index and volatility index. Earnings per share declined from $4.32 to -$3.0699, EBIT declined 162.36% from $129.17M to -$80.55M, and operating cash flow declined 162.18% from $139.39M to -$86.67M.
Esperion Therapeutics, Inc. (ESPR) was downgraded to D- from D on 11/9/2020 due to a substantial decline in the growth index, total return index and volatility index. Earnings per share declined from $4.32 to -$3.0699, EBIT declined 162.36% from $129.17M to -$80.55M, and operating cash flow declined 162.18% from $139.39M to -$86.67M.
D
Sell
5/1/2020Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from D- on 5/1/2020 due to a significant increase in the growth index and volatility index. Operating cash flow increased 13.85% from -$58.03M to -$49.99M, EBIT increased 10.35% from -$65.77M to -$58.96M, and earnings per share increased from -$2.5165 to -$2.2632.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from D- on 5/1/2020 due to a significant increase in the growth index and volatility index. Operating cash flow increased 13.85% from -$58.03M to -$49.99M, EBIT increased 10.35% from -$65.77M to -$58.96M, and earnings per share increased from -$2.5165 to -$2.2632.
D
Sell
11/28/2017Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to D- from D on 11/28/2017 due to a decline in the valuation index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to D- from D on 11/28/2017 due to a decline in the valuation index.
D
Sell
11/13/2017Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from D- on 11/13/2017 due to an increase in the solvency index, valuation index and efficiency index. Total capital increased 79.2% from $156.01M to $279.58M, and the quick ratio increased from 5.4 to 5.81.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from D- on 11/13/2017 due to an increase in the solvency index, valuation index and efficiency index. Total capital increased 79.2% from $156.01M to $279.58M, and the quick ratio increased from 5.4 to 5.81.
D
Sell
8/10/2017Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to D- from D on 8/10/2017 due to a decline in the valuation index, efficiency index and growth index. Total capital declined 19.89% from $194.74M to $156.01M, net income declined 6.9% from -$40.54M to -$43.34M, and EBIT declined 6.78% from -$40.89M to -$43.66M.
Esperion Therapeutics, Inc. (ESPR) was downgraded to D- from D on 8/10/2017 due to a decline in the valuation index, efficiency index and growth index. Total capital declined 19.89% from $194.74M to $156.01M, net income declined 6.9% from -$40.54M to -$43.34M, and EBIT declined 6.78% from -$40.89M to -$43.66M.
D
Sell
2/3/2017Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from D- on 2/3/2017 due to an increase in the volatility index, total return index and valuation index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from D- on 2/3/2017 due to an increase in the volatility index, total return index and valuation index.
D
Sell
9/29/2016Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to D- from D on 9/29/2016 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 32.45 to 27.14.
Esperion Therapeutics, Inc. (ESPR) was downgraded to D- from D on 9/29/2016 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 32.45 to 27.14.
D
Sell
3/11/2016Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
D
Sell
2/26/2016Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to D+ from C- on 2/26/2016 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 28.58% from -$11.83M to -$8.45M.
Esperion Therapeutics, Inc. (ESPR) was downgraded to D+ from C- on 2/26/2016 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 28.58% from -$11.83M to -$8.45M.
C
Hold
2/12/2016Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to C- from D+ on 2/12/2016 due to a substantial increase in the volatility index, valuation index and growth index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to C- from D+ on 2/12/2016 due to a substantial increase in the volatility index, valuation index and growth index.
D
Sell
11/6/2015Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D+ from D on 11/6/2015 due to a noticeable increase in the growth index and efficiency index. Operating cash flow increased 37.33% from -$8.61M to -$11.83M, EBIT increased 3.67% from -$12.46M to -$12.92M, and earnings per share increased from -$0.5517 to -$0.57.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D+ from D on 11/6/2015 due to a noticeable increase in the growth index and efficiency index. Operating cash flow increased 37.33% from -$8.61M to -$11.83M, EBIT increased 3.67% from -$12.46M to -$12.92M, and earnings per share increased from -$0.5517 to -$0.57.
D
Sell
11/5/2015Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to D from D+ on 11/5/2015 due to a significant decline in the volatility index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to D from D+ on 11/5/2015 due to a significant decline in the volatility index.
D
Sell
8/31/2015Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D+ from D on 8/31/2015 due to an increase in the valuation index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D+ from D on 8/31/2015 due to an increase in the valuation index.
D
Sell
6/16/2015Downgrade
Esperion Therapeutics, Inc. (ESPR) was downgraded to D from D+ on 6/16/2015 due to a decline in the total return index.
Esperion Therapeutics, Inc. (ESPR) was downgraded to D from D+ on 6/16/2015 due to a decline in the total return index.
D
Sell
5/8/2015Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D+ from D on 5/8/2015 due to a significant increase in the volatility index, total return index and efficiency index. Total capital increased 130.57% from $138.49M to $319.31M, and net income increased 21.24% from -$9.46M to -$11.47M.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D+ from D on 5/8/2015 due to a significant increase in the volatility index, total return index and efficiency index. Total capital increased 130.57% from $138.49M to $319.31M, and net income increased 21.24% from -$9.46M to -$11.47M.
D
Sell
7/1/2014Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from D- on 7/1/2014 due to a noticeable increase in the total return index and efficiency index.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D from D- on 7/1/2014 due to a noticeable increase in the total return index and efficiency index.
D
Sell
3/3/2014Upgraded
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 3/3/2014 due to an increase in stability.
Esperion Therapeutics, Inc. (ESPR) was upgraded to D- from E+ on 3/3/2014 due to an increase in stability.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
